TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06014502: Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

Sponsor: ImmunoGenesis · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 105 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,539,384

Rescue Site Savings

+$1,005,312

Unlock Full NCT06014502 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06014502 Rescue Dossier →